The aberrantly expressed miRNAs then exert their effect by targeting BCR::ABL1, CML LSCs, pathways implicit in therapy resistance, and drug transporters. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.